Leading the way to safer medication
 Crosscheck  Recommender

Acalabrutinib

Description

Acalabrutinib is a small-molecule inhibitor of BTK (Bruton’s tyrosine kinase). Acalabrutinib and its active metabolite, ACP-5862, form a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. In nonclinical studies, acalabrutinib inhibited BTK-mediated activation of downstream signaling proteins CD86 and CD69 and inhibited malignant B-cell proliferation and tumor growth in mouse xenograft models.

ATC Classification

Code
Title
Category
L01EL02
Acalabrutinib
L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EL Bruton's tyrosine kinase (BTK) inhibitors

Trade names

Trade name
Countries

Australia Austria Canada France Netherlands

Product Monographs

Monograph
Type
Country
CALQUENCE Capsule
MPI, US: SPL/PLR
US